glp-1/gip dual agonist Understand Tirzepatide and Its Effect on Current Weight Loss Therapy glp 1 gip dual agonist
Description
Recent phase 3 TRIUMPH4 data (Dec 2025) showed 28.7% loss over 68 weeks, exceeding semaglutide (1517.5%) and tirzepatide (22.5%)
Furthermore, the EMA has withdrawn the weight loss medication rimonabant, a selective cannabinoid type 1 receptor antagonist, due to its reported links to increased risks of depression and suicide [70]
Though the medication is associated with weight loss and aiding with conditions like type 2 diabetes, it is not a perfect solution to the problem
In this review, the application of GLP-1RAs in neuro-ophthalmology is discussed in detail
doi: 10.1002/cne.902280204 [DOI] [PubMed] [Google Scholar] 184
